Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Myeloma(MM)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03450057
What this trial is testing

Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Hellenic Society of Hematology 38
Testing effectiveness (Phase 2)Study completedNCT05228470
What this trial is testing

Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Who this might be right for
ElranatamabMyelomaMultiple Myeloma+8 more
Pfizer 39
Testing effectiveness (Phase 2)Study completedNCT01793051
What this trial is testing

Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 88
Early research (Phase 1)Study completedNCT01233895
What this trial is testing

Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma

Who this might be right for
Multiple Myeloma
Sanofi 26
Not applicableLooking for participantsNCT07547007
What this trial is testing

Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)
Centre Hospitalier Metropole Savoie 86
Early research (Phase 1)UnknownNCT05438394
What this trial is testing

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM

Who this might be right for
Multiple Myeloma
Peking University People's Hospital 24
Not applicableUnknownNCT04727294
What this trial is testing

MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey

Who this might be right for
Multiple MyelomaSmoldering Multiple MyelomaMonoclonal Gammopathy of Undetermined Significance+1 more
HealthTree Foundation 1,500
Not applicableUnknownNCT04447573
What this trial is testing

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd. 20
Not applicableLooking for participantsNCT06821880
What this trial is testing

Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project

Who this might be right for
Chronic Lymphocytic Leukaemia (CLL)Multiple Myeloma (MM)Secondary Immunodeficiency (SID)
Medical University Innsbruck 120
Not applicableNot Yet RecruitingNCT07253103
What this trial is testing

Effects of a Resistance Physical Exercise Program in Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma (MM)ExerciseCancer
University of Salamanca 50
Early research (Phase 1)Study completedNCT03275103
What this trial is testing

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Who this might be right for
Multiple Myeloma
Genentech, Inc. 355
Early research (Phase 1)Study completedNCT01582295
What this trial is testing

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Who this might be right for
Multiple Myeloma
Massachusetts General Hospital 4
Testing effectiveness (Phase 2)Looking for participantsNCT06106945
What this trial is testing

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Who this might be right for
Multiple Myeloma
AstraZeneca 226
Testing effectiveness (Phase 2)UnknownNCT05998928
What this trial is testing

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

Who this might be right for
Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 10
Not applicableLooking for participantsNCT06933277
What this trial is testing

Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients

Who this might be right for
Multiple Myeloma
Gruppo Italiano Malattie EMatologiche dell'Adulto 159
Testing effectiveness (Phase 2)Active Not RecruitingNCT04883242
What this trial is testing

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
University of Washington 30
Early research (Phase 1)Study completedNCT00642954
What this trial is testing

Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Merck Sharp & Dohme LLC 31
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Early research (Phase 1)Study completedNCT02992483
What this trial is testing

Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Novartis Pharmaceuticals 31
Testing effectiveness (Phase 2)Enrolling By InvitationNCT03815279
What this trial is testing

A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)

Who this might be right for
Multiple MyelomaSmoldering Multiple Myeloma
Landspitali University Hospital 80
Next Page